A carregar...
Prophylaxis of respiratory syncytial virus in Canada in 2003
Passive immunization of high-risk children with the humanized monoclonal antibody palivizumab is the mainstay of respiratory syncytial virus (RSV) prophylaxis in Canada in 2003. This product appears to be safe, and it prevents the majority of RSV hospitalizations in infants born before 36 weeks gest...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Pulsus Group Inc
2003
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2795269/ https://ncbi.nlm.nih.gov/pubmed/20019851 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|